NEW YORK (AP) - Amgen's experimental osteoporosis drug denosumab could have difficulty gaining Food and Drug Administration approval in its initial try, due to a higher incidence of infections compared with placebo seen in some patients, according to an osteoporosis doctor who conducted clinical trials for Amgen. ...
Anytime
